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s it Ever Too Late to Operate
n the Patient With Valvular Heart Disease?
lase A. Carabello, MD, FACC
ouston, Texas
All valvular heart disease imparts a hemodynamic burden on the left and/or right ventricle.
This burden can only be removed effectively by correcting the responsible valvular lesion.
Although a percutaneous approach is usually used to correct mitral stenosis, other valve
lesions require surgical intervention. Over the past 40 years there has been a persistent
improvement in our understanding of the pathophysiology of valvular heart disease and in the
surgical techniques for correcting it. These factors have acted in concert to alter our view of
the proper timing and applicability of surgery. On one hand it is no longer necessary or even
advisable to delay surgery until advanced symptoms are present, and thus surgery is timed
earlier today than it was even a decade ago. On the other hand, many but not all patients with
far advanced disease, once considered inoperable, are now often helped substantially by valve
surgery. However, selection of which of these very ill patients will or will not benefit from
valve surgery remains a challenge for all of us. It is this group of patients that is addressed in

































ackground. Aortic stenosis (AS) is the most common
alvular lesion affecting U.S. adults and its incidence is
ncreasing, in part because AS is a disease of aging and the
.S. population is getting older. Once viewed as a “degen-
rative” disease, AS now is seen as the result of an active
nflammatory process that has much in common with
therosclerosis (1–3). For the majority of patients, manage-
ent is straightforward. Patients have an excellent progno-
is as long as they remain asymptomatic, even in the face of
evere valvular obstruction (4–6). However, once the classic
ymptoms of angina, syncope, or dyspnea develop, progno-
is drastically worsens if aortic valve replacement (AVR) is
ot performed (Fig. 1). In fact, about 75% of symptomatic
atients will succumb in three years after the onset of
ymptoms without valve replacement. In general symptoms
an be attributed to AS if valve area is 1.0 cm2 or if mean
ransvalvular gradient exceeds 50 mm Hg.
Following AVR for patients whose preoperative left
entricular (LV) function was normal, prognosis is excellent
nd can to return to that of a population unaffected by AS
7). Unfortunately, this excellent outcome does not extend
o those patients with preoperative LV systolic dysfunction
hen the transaortic valve gradient is low (less than a mean
radient of 30 mm Hg) (8–10) (Fig. 2).
athophysiology of left ventricular outflow obstruction. In
ormal subjects there is a small gradient between the LV at
he beginning of ejection that rapidly dissipates so that both
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Manuscript received March 2, 2004; revised manuscript received March 18, 2004,sccepted March 23, 2004.entricular and aortic pressures are nearly identical through-
ut most of systole. In humans, the normal aortic valve area
AVA) is 3.0 to 4.0 cm2. As AS develops, little gradient is
resent until the orifice area becomes less than half of
ormal. The relationship of gradient to orifice area is best
escribed by the Gorlin formula: gradient  CO2/AVA2
here CO  cardiac output and AVA  aortic valve area.
hus, at a CO of 5 l/min and an AVA of 1.3 cm2, the
radient across the aortic valve would be only 15 mm Hg.
owever, as the orifice area shrinks by half again to 0.65
m2, the gradient would exceed 60 mm Hg if output
emained constant. At this valve area the LV would have to
enerate a systolic pressure of at least 180 mm Hg to
aintain a normal aortic systolic pressure of 120 mm Hg.
hus, a pressure overload is placed upon the LV. It is
enerally held that this overload is compensated by concen-
ric LV hypertrophy (11). The law of LaPlace states that the
oad or stress on any part of the myocardium is equal to
entricular pressure  radius/2  thickness. Thus, as the
ressure term in the numerator increases, it can be compen-
ated by an increase in thickness in the denominator, and
entricular wall stress (afterload) remains normal despite the
ressure overload. Ejection fraction (EF), a key measure of
entricular performance, is inversely related to afterload
Fig. 3) (11). Thus as a mechanism for maintaining normal
all stress, hypertrophy is compensatory because it also
elps maintain ejection performance. However, the individ-
al hypertrophic response to any given pressure overload is
emarkably variable. In some patients, just enough increase
n wall thickness develops to normalize wall stress and EF is
n the normal range (11). In other patients the amount of
oncentric hypertrophy is marked, wall stress is actually
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July 21, 2004:376–83 Is it Ever Too Late to Operate?atients, the amount of hypertrophy that develops is inad-
quate to normalize stress, and excess wall stress leads to a
educed EF. In most cardiac diseases, prognosis is related to
V performance because in most cardiac diseases LV
erformance is an expression of the integrity of the myo-
ardium and its innate ability to generate force (contractil-
ty). However, in patients with AS in whom hypertrophy
ailed to normalize wall stress (afterload), the resultant
eduction in EF does not indicate contractile dysfunction,
nd prognosis following AVR is excellent (13). This good
rognosis stems from the fact that following surgery in such
atients, aortic obstruction is removed, afterload is therefore
bruptly reduced, and ejection performance improves
ramatically.
he patient with low gradient, low output, and low
F. In patients whose EF is reduced because of afterload
xcess, prognosis remains good because contractility is
aintained so that EF improves once the afterload excess is
emoved. However as shown in Figure 4, in the group of
atients with low gradient and low CO, EF is depressed in
xcess of what would have occurred through afterload excess
lone (8). In such cases there is severe depression in
ontractile function. Myocardial dysfunction in AS, as in
ther heart disease, leads to a poor prognosis. Looking at
he same problem from another point of view, when there is
large transvalvular pressure gradient, relief of that gradient
ollowing AVR causes a large drop in the pressure term in
igure 1. The natural history of aortic stenosis. Survival is nearly normal un
Abbreviations and Acronyms
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve replacement
CO  cardiac output
EF  ejection fraction
LV  left ventriclebruptly declines. Reprinted from Ross and Braunwald (4) with permission.he LaPlace equation, a large reduction in afterload, and
hus a substantial increase in EF. On the other hand, when
he transvalvular gradient is small, there is a correspondingly
maller reduction in afterload and thus a smaller improve-
ent in EF following surgery.
Since my colleagues and I first directed attention toward
his group of patients, understanding about the condition’s
athophysiology and its therapy has evolved substantially. In
hat first report, we noted 14 patients with AS who had
educed EF and congestive heart failure (8). Four of the 14
ad mean transvalvular gradients of 30 mm Hg and all
ither died or failed to improve after AVR, whereas the 10
atients with higher gradients all improved following AVR.
ubsequently, several other reports confirmed and extended
hese findings. Lund noted that prognosis following AVR
aried indirectly with gradient in a group of more than 600
atients with AS (14). Patients with mean gradients of
125 mm Hg had the longest survival post AVR, whereas
atients with gradients of 35 mm Hg had the shortest
urvival and patients with gradients intermediate to those
xtremes had intermediate survival. Brogan et al. (9) exam-
ned 18 patients with AS and a mean gradient of 30 mm
g. Eight patients (44%) did poorly following AVR,
onfirming the poor prognosis of this group of patients.
owever, 10 patients improved following surgery, demon-
trating that not all such patients were doomed to a poor
utcome. This premise was confirmed in a much larger
roup of patients reported by Connolly et al. (10). Operative
ortality was 21%, and 50% had succumbed by four years
ollowing AVR. However, many patients improved symp-
omatically, and several had dramatic increases in EF
ollowing relief of the outflow obstruction. A recent obser-
ational study from the Cleveland Clinic indicates that as a
roup this low-gradient, low-EF group does better with
urgery than with medical therapy (15). Although this study
as not a randomized clinical trial, careful matching of
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Is it Ever Too Late to Operate? July 21, 2004:376–83atients who did versus those who did not receive an AVR
uggested that patients with similar hemodynamics and
omorbidities preoperatively had much better results with
VR. Almost all medically treated patients were dead
ithin three years after identification, compared with a 75%
urvival in patients with AVR. Although not all preopera-
ive biases were likely accounted for, the extraordinary
enefit from AVR in this very ill (and highly selected) group
s convincing about the potential benefits of AVR in this
roup. Still, when all the data are taken together it seems
nwise to recommend surgery to all low-gradient, low-EF
atients. Rather, it seems advisable to try to risk-stratify
atients before surgery in order to deicide whether medical
r surgical therapy is best for a given patient. This stratifi-
ation is based on 1) stenosis severity, 2) inotropic reserve,
) the presence or absence of coronary disease or other valve
isease, and 4) other comorbidities.
S severity. Logically, the more severe the stenosis, the
reater the benefit from relief of the obstruction. From
nother viewpoint, for the disease to have resulted in severe
ystolic failure the obstruction must have been so severe
hat, in turn, stenosis relief should lead to improved func-
ion. Indeed, it is hard imagine that replacement of mild-
igure 2. Survival following surgery for aortic stenosis patients with low
radient and low ejection fraction. Operative mortality was 21%, and less
han half of the patients survived four years. Reprinted from Connolly et al.
10) with permission.
igure 3. Ejection fraction plotted against afterload (mean systolic wall
tress) for aortic stenosis patients demonstrates and excellent inverseHorrelation. Reprinted from Gunther and Grossman (11) with permission.o-moderate disease that preoperatively had produced a 5 to
0 mm Hg gradient would even be entertained. At first
lush, this principle should be dealt with easily. Patients
ith severe AS (i.e., a valve area of 1.0 cm2) should
ndergo AVR. Unfortunately, valve area, especially valve
rea calculated at low flow either by the Gorlin or continuity
quations, is often inaccurate because of the flow depen-
ence of the calculation (16–18). Calculated valve area is
maller, often dramatically so, at lower CO. Debate contin-
es as to whether this flow dependence represents a real
hange in orifice area or is due to inherent problems with
he formulas. Different studies support both points of view.
n the first instance it is presumed that greater output
hrough a stenotic valve opens the valve to a larger orifice
rea that is reflected more or less accurately by the increased
alculated valve area. In the second instance the fact that the
ischarge coefficients for the Gorlin formula as it pertains to
he aortic valve were never developed may play a role.
urrently a common practice for establishing whether or
ot truly severe AS is present at low CO is to increase
utput pharmacologically (usually with dobutamine). If
radient increases in concert with output, valve area will
ncrease only slightly, and it is presumed that severe fixed
alvular obstruction is present. In other cases increased
utput may result in a significant increase in valve area of
0.3 cm2 or calculated valve area exceeds 1.0 cm2, a
ondition sometimes referred to as aortic pseudostenosis
19). For this calculated result to occur, there must be a
ubstantial increase in output without a large increase in
radient, which logically means severe obstruction is absent.
igure 4. A relationship similar to that shown in Figure 3 is plotted for
ortic stenosis patients with low ejection fraction. Four patients (Xs) had
epressed ejection fraction out of proportion to afterload and had a poor
utcome following AVR. These patients had a mean aortic gradients of
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July 21, 2004:376–83 Is it Ever Too Late to Operate?mall studies, and thus its exact role in decision-making is
till unclear. Pharmacologic manipulation was not used in
he study (15) where patients with low gradient and low
utput benefited from AVR. Thus, it is possible that some
f the patients who benefited from AVR could have had
seudostenosis. Valve resistance, which is simply mean
radient divided by CO per beat, has been used as an
djunct to valve area in making the distinction between truly
evere and milder AS (16). Resistance has the potential
dvantage over area because it involves no discharge coeffi-
ients and because removing the square root sign over the
radient raises the importance of gradient and diminishes
he importance of output, making the calculation less output
ependent. However, because resistance has never been
stablished as superior to valve area, and because no critical
alue has been established, resistance must be considered
xperimental at present.
notropic reserve. Irrespective of whether gradient in-
reases appropriately with output during dobutamine infu-
ion, the failure of output itself to increase during inotropic
hallenge has been convincingly shown to impart a poor
rognosis in several studies (20–22) (Fig. 5). Presumably
he absence of inotropic reserve defines both severe and
rreversible LV dysfunction, in turn imparting a bad out-
ome following AVR. Thus, AVR seems inadvisable for AS
atients whose CO does not increase by at least 25% during
obutamine challenge, although even some patients who
ave failed inotropic challenge have improved following
VR (22).
oronary artery disease. In most studies of patients with
S, the copresence of coronary artery disease negatively
ffects prognosis, and this is true for low-gradient low-EF
S patients as well (10). Reduced prognosis stems from that
act that a second dangerous cardiac disease is now present
n conjunction with AS. Additionally, those portions of the
entricle that are dead cannot benefit from the afterload
eduction of AVR. On the other hand, if it were clear that
ome of the LV dysfunction that was present was in fact due
o hibernating myocardium, substantial recovery in function
ould occur post-operatively, not just from the benefits of
VR but also from those of revascularization.
In summary, most patients with AS, even those with low
radient and low output, benefit from AVR. Patients
ithout inotropic reserve and those with a large increase in
VA with increased output are least likely to benefit,
lthough even some in this group may improve following
urgery. As yet, a method for defining this last group has yet
o be elucidated.
ONISCHEMIC MITRAL REGURGITATION
athophysiology. Mitral regurgitation imposes a “pure”
olume overload on the LV. The volume regurgitated into
he left atrium decreases forward stroke volume. This loss is
ompensated by eccentric hypertrophy whereby additional
arcomeres are laid down in series, increasing the length of Tach myocyte. In turn, cell lengthening increases the volume
f the ventricle, enabling it to increase total and forward
troke volume. This overload is tolerated for a variable
eriod, but eventually volume overload causes LV dysfunc-
ion. Dysfunction is characterized by a loss of myofibrils
23) and by a blunting of the myocardial force-frequency
elationship (24), suggesting compromised calcium han-
ling. As dysfunction develops, activation of the sympa-
hetic nervous system supports inotropic state but leads also
o further myocardial damage (25,26). Both experimental
nd human data indicate that this damage can be reversed
y mitral valve repair/replacement (27,28) or by institution
f beta-blockade (29).
The onset of muscle dysfunction is often hidden by the
avorable loading conditions created by the second pathway
or ejection of blood (into the left atrium) present in mitral
egurgitation. This second pathway tends to reduce after-
oad while the volume overload itself increases preload, both
ffects acting in concert to increase EF to a higher than
ormal value (30).
iming of surgery. Obviously surgery should be performed
efore the advent of the deleterious processes noted earlier.
linically the current best markers that function is declining
re the development of symptoms (31) and the presence of
chocardiographic markers of systolic failure. Because post-
perative results worsen when either EF falls to 0.60 or
hen end-systolic dimension approaches 45 mm, it is
resumed that these markers herald the onset of muscle
ysfunction (32–34).
s EF ever so low that it precludes valve surgery? To
nswer this question, some misconceptions about the phys-
ologic effects of restoring mitral valve competence must be
esolved. Until about two decades ago, the nearly universal
bservation was that EF fell following mitral valve replace-
ent for mitral regurgitation. It was assumed that this was
he inevitable consequence of removing the favorable load-
ng conditions created by mitral regurgitation noted above.
igure 5. Survival for aortic stenosis patients with low gradient and low
jection fraction. Group I patients demonstrated inotropic reserve and had
better outcome with AVR than did similar patients treated medically, and
etter than group II patients who lacked inotropic reserve. Reprinted from
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Is it Ever Too Late to Operate? July 21, 2004:376–83reload and increase afterload, forcing EF to fall. Thus, if
F were already reduced, surgery would lower it yet further,
aking operation untenable in advanced LV dysfunction.
lthough logical, this scenario turns out to be false. Mitral
alve surgery two decades ago usually involved mitral valve
eplacement during which the mitral apparatus was re-
oved, which at the time was thought to be inconsequen-
ial. It was not recognized that the mitral valve and its
pparatus were an important functional component of the
V, helping to maintain its shape and contractility (35). We
ow know it is primarily destruction of the valve apparatus
nd not the loading changes that result in reduced EF
ollowing mitral surgery. We know this because mitral
epair, which restores competence without destroying the
pparatus, causes little or no reduction in EF (36,37) (Fig.
). In fact, afterload actually falls rather than rises following
epair because the radius term in the LaPlace equation is
educed (37). Recently, Bach and Bolling (38) have reported
uccessful mitral annuloplasty in patients with EFs of
0.20. Thus, almost no one with mitral regurgitation
ithout other comorbidities is inoperable in experienced
ands, no matter how low the EF, provided that the valve
pparatus is conserved during surgery. On the other hand, if
he valve and its attachments cannot be preserved, valve
eplacement for patients with EFs of 0.35 is probably
nadvisable.
These comments pertain to nonischemic mitral regurgi-
ation. Ischemic mitral regurgitation has less favorable
esults at any level of LV dysfunction, in part because by
efinition there is a second potentially fatal cardiac disease
resent. On the other hand, revascularization of viable
yocardium during valve surgery may improve function.
he complexity of ischemic mitral regurgitation makes
ecommendation about inoperability in this disease quite
roblematic. Unlike in nonischemic mitral regurgitation,
here valve repair is clearly the treatment of choice, in
igure 6. Left ventricular (LV) ejection fraction is shown pre- and
ostoperatively for patients who had mitral apparatus preservation versus
hose with apparatus removal. Reprinted from Rozich et al. (37) with
ermission.schemic disease repair seems to benefit patients with the pest preoperative function and fewest comorbidities (39).
resumably, in the highest risk patients prognosis is so
ompromised that the type of surgery performed has little
ffect on this poor outcome.
ITRAL STENOSIS
athophysiology. As with AS, little hemodynamic distur-
ance develops until orifice size is compromised to less than
alf of the normal mitral valve area (4.0 to 5.0 cm2). At that
oint the small early diastolic gradient normally present at
he beginning of systole increases in duration and magni-
ude, raising left atrial pressure and pulmonary artery
ressure modestly. As valve area narrows further, left atrial
ypertension leads to pulmonary congestion; at the same
ime the reduced orifice area limits CO, mimicking LV
ailure. In fact, in most cases of mitral stenosis LV contrac-
ility is normal. However, in about one-third of mitral
tenosis patients, reduced preload caused by limited mitral
nflow and increased afterload precipitated by reflex vaso-
onstriction secondary to decreased CO act in concert to
educe ejection performance (40). With still further mitral
alve narrowing, secondary pulmonary vasoconstriction
orsens pulmonary hypertension, resulting eventually in
ight ventricular failure.
iming of mechanical intervention. Unlike the other
alve lesions, mitral stenosis can be corrected in most cases
ercutaneously using balloon valvotomy. In cases where
xtensive calcification and valve deformity preclude balloon
alvotomy, surgical commissurotomy or mitral valve re-
lacement is performed. Because sudden death is extraor-
inarily rare in asymptomatic patients, there is little to
ompel mechanical intervention before symptom develop-
ent. The exception to this rule is the development of
symptomatic pulmonary hypertension. Pulmonary hyper-
ension increases surgical mortality by up to fourfold, and
hus intervention should be performed once pulmonary
ypertension is detected, irrespective of the presence of
ymptoms (41) (Fig. 7). Otherwise, mechanical intervention
hould be provided once more than mild symptoms are
igure 7. Postoperative outcome is shown for mitral stenosis patients with
ulmonary hypertension. Long-term outcome was good but followed a
igh (12%) operative mortality. Reprinted from Vincens et al. (41) with
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July 21, 2004:376–83 Is it Ever Too Late to Operate?s it ever too late to intervene mechanically in mitral
tenosis? It is important to realize that whereas pulmonary
ypertension worsens prognosis in mitral stenosis, pulmo-
ary pressure usually returns to or toward normal following
uccessful intervention. Thus, the presence of even severe
ulmonary hypertension and right heart failure are not
ontraindications for valvotomy or surgery. Further reassur-
nce that pulmonary pressure will fall following surgery can
e gleaned from preoperative inhalation of nitric oxide (42).
significant fall in pulmonary pressure preoperatively with
his test usually indicates that pulmonary pressure will revert
oward normal postoperatively. In general, it is almost never
oo late to provide mechanical correction for mitral stenosis.
ven when severe comorbidities exist, an attempt at balloon
alvotomy is usually warranted and is often successful.
ORTIC REGURGITATION
athophysiology. Although both mitral and aortic regur-
itation impart a volume overload on the LV, the patho-
hysiologies of the two lesions are actually quite different
rom one another (43). In aortic regurgitation the extra
olume that leaked into the LV during diastole is expelled
nto the aorta during diastole. Thus, total aortic stroke
olume is large whereas forward stroke volume is reduced.
ecause pulse pressure is directly related to stroke volume,
ulse pressure is widened in patients with aortic regurgita-
ion, in turn producing almost obligate systolic hyperten-
ion. On the other hand, in mitral regurgitation the extra
troke volume is pumped into the left atrium, and thus
ortic stroke volume is reduced and systolic blood pressure
ends to be low. Therefore in aortic regurgitation there is
oth volume and pressure overload, whereas in mitral
egurgitation, the volume overload is pure. These differences
n load cause differences in LV geometry and in the response
f the LV to valve replacement. In aortic regurgitation there
s not only increased chamber size, but also a modest
ncrease in wall thickness while in mitral regurgitation wall
hickness tends to be less than normal (44). Preload is
ncreased in both conditions; in aortic regurgitation there is
ften substantial afterload excess whereas afterload is nor-
al in mitral regurgitation. These different loading condi-
ions result in different changes in load and in LV perfor-
ance following valve replacement or repair. As noted
efore, following mitral valve repair afterload is modestly
educed and preload is also reduced, netting no change in
ostoperative EF. If the mitral valve apparatus is destroyed
t surgery, afterload increases postoperatively, preload de-
reases, and EF falls significantly. In contrast, following
VR, systolic hypertension disappears, afterload is greatly
ecreased, and EF increases, often returning to normal even
f preoperative depression is severe (45,46) (Fig. 8).
iming of surgery. As with mitral regurgitation, surgery
or correction of aortic regurgitation should be performed
hen even mild symptoms appear because further delay
orsens prognosis (47). As with mitral regurgitation, gsymptomatic LV dysfunction can develop in aortic regur-
itation. Because excess afterload reduces ejection perfor-
ance in aortic regurgitation, somewhat worse ejection
erformance can be present in aortic regurgitation than in
itral regurgitation without indicating depressed contrac-
ility and irreversible myocardial damage. Thus surgery
hould occur before EF falls below 0.55 or before end-
ystolic dimension exceeds 55 mm (48). Because some cases
f sudden death have been reported in patients with very
arge LVs, surgery should also be contemplated for an
nd-diastolic dimension of 75mm.
s it ever too late for AVR in aortic regurgitation? As
oted earlier, the element of afterload excess present in
atients with aortic regurgitation improves following valve
eplacement, in turn increasing ejection performance while
educing filling pressure and increasing forward CO. Thus,
VR should be offered to most patients, even though they
ave missed the opportunity for the best surgical outcome
nd even when EF is depressed and end-systolic dimension
xceeds 55 mm. Although there are few data to support the
oncept, patients unable to generate an LV pressure above
20 mm Hg are likely to have less afterload reduction
ollowing AVR and are probably very poor surgical
andidates.
ummary. Over the past three decades the best timing for
alve replacement and guidelines for it have been developed
nd confirmed. However, some patients still come to med-
cal attention well beyond this optimal timing window.
ven in most of these, advances in surgical technique allow
ost to be operated successfully, although prognosis is still
educed in such patients. Aortic stenosis patients with low
igure 8. Ejection fraction is plotted against afterload for aortic regurgi-
ation patients before and after aortic valve replacement for patients with
reserved and patients with depressed preoperative ejection fraction. In
oth groups, afterload decreased and ejection fraction increased following
urgery. Triangles  Group 1 (n  23); squares  Group 2 (n  6);
ircles  normal subjects. Reprinted from Taniguchi et al. (45) with
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Is it Ever Too Late to Operate? July 21, 2004:376–83egurgitation patients with low EF in whom the valve
pparatus cannot be preserved constitute the small group of
atients in whom valve replacement should probably not be
erformed.
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